We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
HLS Therapeutics Inc | TSX:HLS | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 2.82% | 3.65 | 3.56 | 3.74 | 3.70 | 3.65 | 3.70 | 700 | 20:01:44 |
TORONTO, Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will take part in a fireside chat with Stifel Healthcare analyst, Justin Keywood, at the 2022 Stifel Healthcare Conference on Wednesday November 16, 2022 at 8:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City.
The Company's fireside chat will be webcast at: https://wsw.com/webcast/stifel74/hls.to/2368752
HLS will also host one-on-one meetings with investors at the conference. To request a one-on-one meeting, please contact your Stifel representative.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
Copyright 2022 Canada NewsWire
1 Year HLS Therapeutics Chart |
1 Month HLS Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions